Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

EQS-Adhoc: Preliminary half-year figures – total volume and gross profit in line with plan, EBT significantly below previous year
EQS-Adhoc: Preliminary half-year figures – total volume and gross profit in line with plan, EBT significantly below previous year
EQS-Adhoc: Preliminary half-year figures – total volume and gross profit in line with plan, EBT significantly below previous year
EQS-News: Mountain Alliance AG publishes half-year financial statements 2025 – Net asset value per share at €6.01
EQS-News: Mountain Alliance AG publishes half-year financial statements 2025 – Net asset value per share at €6.01
EQS-News: Mountain Alliance AG publishes half-year financial statements 2025 – Net asset value per share at €6.01
EQS-News: PLANOPTIK AG: Half-year financial report as of June 30, 2025
EQS-News: PLANOPTIK AG: Half-year financial report as of June 30, 2025
EQS-News: PLANOPTIK AG: Half-year financial report as of June 30, 2025
EQS-News: Heidelberg Pharma Advances to Cohort 9 in Phase I/IIa Trial of Lead ATAC Candidate HDP-101 in Multiple Myeloma
EQS-News: Heidelberg Pharma Advances to Cohort 9 in Phase I/IIa Trial of Lead ATAC Candidate HDP-101 in Multiple Myeloma
EQS-News: Heidelberg Pharma Advances to Cohort 9 in Phase I/IIa Trial of Lead ATAC Candidate HDP-101 in Multiple Myeloma
EQS-News: Heidelberg Pharma Significantly Reduces Operating Costs and Focuses on Lead ADC Candidate HDP-101 Due to Delayed Milestone Payment
EQS-News: Heidelberg Pharma Significantly Reduces Operating Costs and Focuses on Lead ADC Candidate HDP-101 Due to Delayed Milestone Payment
EQS-News: Heidelberg Pharma Significantly Reduces Operating Costs and Focuses on Lead ADC Candidate HDP-101 Due to Delayed Milestone Payment
EQS-Adhoc: Heidelberg Pharma Significantly Reduces Operating Costs and Focuses on Lead ADC Candidate HDP-101 Due to Delayed Milestone Payment
EQS-Adhoc: Heidelberg Pharma Significantly Reduces Operating Costs and Focuses on Lead ADC Candidate HDP-101 Due to Delayed Milestone Payment
EQS-Adhoc: Heidelberg Pharma Significantly Reduces Operating Costs and Focuses on Lead ADC Candidate HDP-101 Due to Delayed Milestone Payment
EQS-News: PAL Next AG: First Half of 2025 in Line with Expectations
EQS-News: PAL Next AG: First Half of 2025 in Line with Expectations
EQS-News: PAL Next AG: First Half of 2025 in Line with Expectations
EQS-News: aconnic AG announces changes in the Supervisory Board: Dr. Stefan Hagemann is stepping down from the supervisory board und will remain managing director of the subsidiary aconnic carbonzero GmbH
EQS-News: aconnic AG announces changes in the Supervisory Board: Dr. Stefan Hagemann is stepping down from the supervisory board und will remain managing director of the subsidiary aconnic carbonzero GmbH
EQS-News: aconnic AG announces changes in the Supervisory Board: Dr. Stefan Hagemann is stepping down from the supervisory board und will remain managing director of the subsidiary aconnic carbonzero GmbH
EQS-News: Camerit AG Half-year results for the first half of 2025
EQS-News: Camerit AG Half-year results for the first half of 2025
EQS-News: Camerit AG Half-year results for the first half of 2025
EQS-News: Bastei Lübbe AG: Annual General Meeting confirms successful business development – dividend increased again
EQS-News: Bastei Lübbe AG: Annual General Meeting confirms successful business development – dividend increased again
EQS-News: Bastei Lübbe AG: Annual General Meeting confirms successful business development – dividend increased again
EQS-Adhoc: CHAPTERS Group AG: Capital Increase against contribution in kind from Authorized Capital resolved
EQS-Adhoc: CHAPTERS Group AG: Capital Increase against contribution in kind from Authorized Capital resolved
EQS-Adhoc: CHAPTERS Group AG: Capital Increase against contribution in kind from Authorized Capital resolved
EQS-News: PLANOPTIK AG: Trading commences on the regulated market (General Standard)
EQS-News: PLANOPTIK AG: Trading commences on the regulated market (General Standard)
EQS-News: PLANOPTIK AG: Trading commences on the regulated market (General Standard)
EQS-News: Reporting of Preliminary Results for the first half of 2025
EQS-News: Reporting of Preliminary Results for the first half of 2025
EQS-News: Reporting of Preliminary Results for the first half of 2025
EQS-News: HelloFresh SE Announces Intention of Co-Founder and CEO International, Thomas Griesel, to Depart
EQS-News: HelloFresh SE Announces Intention of Co-Founder and CEO International, Thomas Griesel, to Depart
EQS-News: HelloFresh SE Announces Intention of Co-Founder and CEO International, Thomas Griesel, to Depart
EQS-Adhoc: HelloFresh SE: Thomas Griesel, co-founder and CEO International of HelloFresh SE, does not intend to extend his Management Board mandate beyond 30 April 2026
EQS-Adhoc: HelloFresh SE: Thomas Griesel, co-founder and CEO International of HelloFresh SE, does not intend to extend his Management Board mandate beyond 30 April 2026
EQS-Adhoc: HelloFresh SE: Thomas Griesel, co-founder and CEO International of HelloFresh SE, does not intend to extend his Management Board mandate beyond 30 April 2026
EQS-News: Heidelberg Pharma Announces New Clinical Data on Lead ATAC Candidate HDP-101 to be Presented at International Myeloma Society Annual Meeting 2025
EQS-News: Heidelberg Pharma Announces New Clinical Data on Lead ATAC Candidate HDP-101 to be Presented at International Myeloma Society Annual Meeting 2025
EQS-News: Heidelberg Pharma Announces New Clinical Data on Lead ATAC Candidate HDP-101 to be Presented at International Myeloma Society Annual Meeting 2025
EQS-News: The Payments Group Holding – Results of the Annual General Meeting and Supervisory Board Meeting
EQS-News: The Payments Group Holding – Results of the Annual General Meeting and Supervisory Board Meeting
EQS-News: The Payments Group Holding – Results of the Annual General Meeting and Supervisory Board Meeting
EQS-News: Annual Meeting 2025 - DF Group faces new political challenges
EQS-News: Annual Meeting 2025 - DF Group faces new political challenges
EQS-News: Annual Meeting 2025 - DF Group faces new political challenges
EQS-News: SBF AG develops customized lighting control for rolling stock
EQS-News: SBF AG develops customized lighting control for rolling stock
EQS-News: SBF AG develops customized lighting control for rolling stock
EQS-News: Digital Advertising Impact at TV-Level: YOC High-Impact Ads Deliver Comparable Effectiveness to 15-Second TV Spots
EQS-News: Digital Advertising Impact at TV-Level: YOC High-Impact Ads Deliver Comparable Effectiveness to 15-Second TV Spots
EQS-News: Digital Advertising Impact at TV-Level: YOC High-Impact Ads Deliver Comparable Effectiveness to 15-Second TV Spots
EQS-News: Readcrest Capital and KFK Holding launch development joint venture
EQS-News: Readcrest Capital and KFK Holding launch development joint venture
EQS-News: Readcrest Capital and KFK Holding launch development joint venture
EQS-Adhoc: TTL Beteiligungs- und Grundbesitz-AG: Precautionary loss notification pursuant to Section 92 (1) of the German Stock Corporation Act (AktG)
EQS-Adhoc: TTL Beteiligungs- und Grundbesitz-AG: Precautionary loss notification pursuant to Section 92 (1) of the German Stock Corporation Act (AktG)
EQS-Adhoc: TTL Beteiligungs- und Grundbesitz-AG: Precautionary loss notification pursuant to Section 92 (1) of the German Stock Corporation Act (AktG)
EQS-News: Ernst Russ Announces Financial Results for the First Half of 2025
EQS-News: Ernst Russ Announces Financial Results for the First Half of 2025
EQS-News: Ernst Russ Announces Financial Results for the First Half of 2025
EQS-News: Daldrup & Söhne AG increases EBIT margin and specifies EBIT forecast
EQS-News: Daldrup & Söhne AG increases EBIT margin and specifies EBIT forecast
EQS-News: Daldrup & Söhne AG increases EBIT margin and specifies EBIT forecast
EQS-Adhoc: Heidelberg Pharma’s Partner Telix Pharmaceuticals Gives Regulatory Update for its Imaging Agent TLX250-CDx
EQS-Adhoc: Heidelberg Pharma’s Partner Telix Pharmaceuticals Gives Regulatory Update for its Imaging Agent TLX250-CDx
EQS-Adhoc: Heidelberg Pharma’s Partner Telix Pharmaceuticals Gives Regulatory Update for its Imaging Agent TLX250-CDx